Sompraz%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520hp

The provided drug name "Sompraz%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520hp" appears to be corrupted and does not represent a recognized drug name. It is highly likely that the intended drug is **esomeprazole**. The following information is based on esomeprazole. Please verify the correct drug name. ## Overview Esomeprazole is a proton pump inhibitor (PPI) that reduces the amount of acid produced in the stomach. ## Primary Indications * Gastroesophageal reflux disease (GERD) - healing of erosive esophagitis and maintenance of healing, symptomatic GERD. * Eradication of *Helicobacter pylori* infection (in combination with antibiotics). * Prevention of NSAID-associated gastric ulcers in patients at risk. * Treatment of heartburn associated with symptomatic GERD. ## Adult Dosing * **Healing of Erosive Esophagitis:** 20 mg or 40 mg orally once daily for 4 to 8 weeks. * **Maintenance of Healing of Erosive Esophagitis:** 20 mg orally once daily. * **Symptomatic GERD:** 20 mg orally once daily for 4 weeks. * ***H. pylori* Eradication:** Esomeprazole 20 mg twice daily plus clarithromycin 500 mg twice daily and amoxicillin 1 g twice daily for 7 days. * **Prevention of NSAID-Associated Gastric Ulcers:** 20 mg orally once daily. * **Heartburn (Symptomatic GERD):** 20 mg orally once daily. ## Pediatric Dosing Dosing in pediatric patients varies significantly by age and indication. Consult specific pediatric guidelines or product labeling. Generally, for GERD and erosive esophagitis: * **1 to 11 years:** 10 mg or 20 mg orally once daily depending on weight and indication. * **12 to 17 years:** Similar to adult dosing for GERD and erosive esophagitis. ## Dose Adjustments * **Hepatic Impairment:** For severe hepatic impairment, consider reducing the dose. The maximum dose for patients with severe hepatic impairment is 20 mg once daily. * **Renal Impairment:** No dose adjustment is typically required. ## Contraindications * Known hypersensitivity to esomeprazole, substituted benzimidazoles, or any component of the formulation. ## Adverse Effects * **Common:** Headache, diarrhea, nausea, abdominal pain, constipation, flatulence, dry mouth. * **Serious:** *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), hypomagnesemia, vitamin B12 deficiency, lupus erythematosus. ## Key Drug Interactions * **Drugs Dependent on Gastric pH:** PPIs can decrease absorption of drugs requiring acidic gastric pH (e.g., ketoconazole, itraconazole, iron salts, vitamin B12). * **CYP2C19 Substrates/Inhibitors:** Esomeprazole is a CYP2C19 inhibitor. May increase plasma concentrations of drugs metabolized by CYP2C19 (e.g., clopidogrel - reduced antiplatelet effect; voriconazole). * **CYP3A4 Substrates:** May increase plasma concentrations of drugs metabolized by CYP3A4 (e.g., some statins, calcium channel blockers). * **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. ## Monitoring * Monitor for signs and symptoms of *Clostridium difficile*-associated diarrhea. * Monitor serum magnesium levels, especially in patients on long-term therapy or concomitant medications that may cause hypomagnesemia (e.g., diuretics). * Consider monitoring vitamin B12 levels in patients on long-term therapy. * Assess for signs of bone fracture risk. ## Clinical Pearls * Administer at least 1 hour before meals for optimal efficacy. * Capsules can be opened and contents mixed with applesauce for patients with difficulty swallowing, but the mixture should be consumed immediately. Do not chew or crush the granules. * Long-term PPI use is associated with increased risk of fractures, *C. difficile* infection, hypomagnesemia, and vitamin B12 deficiency. Use the lowest effective dose for the shortest duration necessary. * Discontinuation syndrome (rebound acid hypersecretion) can occur. Tapering the dose may be considered. *** **Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and your institution's protocols for definitive guidance.